80 citations
,
April 2017 in “Frontiers in Pharmacology” PDRN helps repair tissue and improve wound healing with a high safety profile.
April 2026 in “The Journal of Steroid Biochemistry and Molecular Biology”
6 citations
,
February 2016 in “Journal of Microencapsulation” Improved finasteride formula allows slow, sustained release and better absorption for patients.
23 citations
,
July 2021 in “International Journal of Pharmaceutics” New dissolving and implantable microneedle patches have been created for a long-lasting, non-invasive delivery of the drug finasteride.
January 2026 in “Andrology” PRP injections are safe but don't significantly improve Peyronie's Disease.
1 citations
,
January 2002 in “PubMed” PM-9, like finasteride, may help treat certain diseases by blocking a key enzyme.
11 citations
,
January 2000 in “The Journal of Steroid Biochemistry and Molecular Biology” LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
December 2013 in “The Journal of Urology”
LGF injections may improve early Peyronie's disease by reducing penile curvature and plaque size.
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
69 citations
,
December 2005 in “Nature Clinical Practice Endocrinology & Metabolism” Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
January 2014 in “Journal of Central South University(Science and Technology)” PPCM microspheres can effectively release finasteride over 42 days.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
March 2026 in “Gazzetta Medica Italiana Archivio per le Scienze Mediche” Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
September 2025 in “Science Advances” PADI4 enzyme slows down cell growth in developing hair follicles.
1 citations
,
October 2013 in “Urology” More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
13 citations
,
January 2005 in “Chemical and Pharmaceutical Bulletin” Smaller substituents at C-17 enhance the inhibitory activity of progesterone derivatives on 5alpha-reductase.
November 2003 in “PubMed” January 2004 in “Data Archiving and Networked Services (DANS)” Finasteride blocks progesterone's effect on brain activity linked to epilepsy.
6 citations
,
August 2021 in “International Journal of Pharmaceutics” A new device, IVL-PPF Microsphere®, was created to deliver a hair loss drug for up to 3 months with one injection, potentially replacing daily pills.
3 citations
,
April 2021 in “Journal of Medicinal Chemistry” Finasteride may affect PNMT, causing side effects.
26 citations
,
October 2011 in “International Journal of Biological Macromolecules” Some newly made compounds are promising for treating enlarged prostate, hair loss, viruses, and prostate cancer, and might be better than current drugs.
Finasteride, a medication, is being re-evaluated for its effects and uses.